Abstract 298P
Background
Cervical Cancer is one of the leading causes of cancer mortality in Indian women.Most of the women present in advanced stages of cervical cancer. Although CTRT remains the standard of care there were several challenges in implementation. In this study we assesed 3-year outcomes of LACC patients and the factors impacted the outcome.
Methods
We retrospectively analysed the records and follow up data of 131 patients of locally advanced cervical cancer registered in 2019. We noted the baseline characteristics include demographic data, comorbidities, histology and stage, treatment details, follow up data which include their disease status, death. Table: 298P
Baseline characterstics
| Variables | N=131 | (%) | |
| Comorbidities | |||
| Diabetes Mellitus | 19 | 14.5 | |
| Hypertension | 18 | 13.7 | |
| Others | 16 | 12.2 | |
| None | 78 | 59.5 | |
| ECOG | |||
| 1 | 98 | 74.8 | |
| 2 | 29 | 22.1 | |
| 3 | 4 | 3.1 | |
| Histology | |||
| Squamous Cell Carcinoma | 121 | 92.4 | |
| Adenocarcinoma | 6 | 4.6 | |
| Others | 4 | 3.1 | |
| Stage (FIGO 2018) | |||
| IB | 8 | 6.1 | |
| IIA | 5 | 3.8 | |
| IIB | 47 | 35.9 | |
| IIIA | 6 | 4.6 | |
| IIIB | 47 | 35.9 | |
| IIIC1 | 9 | 6.9 | |
| IIIC2 | 3 | 2.3 | |
| IVA | 6 | 4.6 |
Results
The median follow-up time was 45.5 months (IQR - 39.7-47.4). 5 patients had defaulted radiotherapy, 5 defaulted brachytherapy and 9 deferred brachytherapy. The average time from diagnosis to start of treatment is 109 days. 3-year OS was 78.6%. Stage-wise survival was IB (100%), IIA (100%), IIB (78.7%), IIIA (83.3%), IIIB (78.7%), IIIC (66.6%) & IVA (50%). 82.4% in CTRT patients and 72.4% in RT alone were alive. Dose >85Gy resulted in better local control and survival. The 3-year OS of patients with Overall Treatment Time <56 days is 89.1% while OTT >56 days is 80.7% (p=0.215).
Conclusions
The findings of this study highlighted the importance of concurrent chemoradiation in locally advanced cervical cancer. Doses >85 Gy to the disease and OTT <56 days showed better outcomes. Strategies to improve compliance to CTRT and image-guided adaptive brachytherapy will help in improved local control and survival. In low-middle income countries, these outcomes are also impacted by non-compliance and long wait-list to treatment, which is often due to logistical and socio-cultural barriers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract